Skip to main content
Premium Trial:

Request an Annual Quote

With 90 Percent of Digene Shares Tendered, Qiagen Preps to Close $1.6B Acquisition

NEW YORK (GenomeWeb News) - Qiagen said its offer to buy all of Digene's outstanding shares expired on Friday night, and that it plans to continue with the acquisition by accepting tendered shares making up more than 90 percent of Digene's stock.
 
Qiagen said it will complete the $1.6 billion deal, without the approval of Digene's stockholders, after the acceptance of the shares.
 
Last week, Qiagen said that its shareholders approved the deal and that it had cleared US federal regulators' Hart-Scott-Rodino antitrust deadline.
 
The company expects the merger to be completed by August or September.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.